The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...
CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today announces the launch of the first offering from its new product range - ioCRISPR-Ready Cells™. This ...
Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.
The disease-relevant mutation is engineered into bit.bio’s human ioWild Type TM cells using CRISPR/Cas9 gene editing. As disease model cells come from an identical human genetic background to ioWild ...
Traditional DRAM technology, with memory bit cells consisting of one silicon transistor and one capacitor, faces major scaling challenges. A new DRAM bit cell without a capacitor and with two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results